Holen Sie sich die Stockscreener-App
8.20
0.61%
0.05
Vorhandelsmarkt:
8.18
-0.02
-0.24%
Schlusskurs vom Vortag:
$8.15
Offen:
$8.16
24-Stunden-Volumen:
15,163
Relative Volume:
0.02
Marktkapitalisierung:
$10.87M
Einnahmen:
$1.47M
Nettoeinkommen (Verlust:
$-97.61M
KGV:
-5.5034
EPS:
-1.49
Netto-Cashflow:
$-80.90M
1W Leistung:
-3.30%
1M Leistung:
-21.53%
6M Leistung:
-14.85%
1J Leistung:
-43.25%
1-Tages-Spanne:
$8.00
$8.44
1-Wochen-Bereich:
$7.85
$8.56
52-Wochen-Spanne:
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Firmenname
Lyra Therapeutics Inc
Sektor
Branche
Telefon
617-373-4600
Adresse
480 ARSENAL WAY, WATERTOWN, MA
Vergleichen Sie LYRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
8.20 | 13.55M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-07 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-05-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-05-06 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-26 | Eingeleitet | BTIG Research | Buy |
| 2020-05-26 | Eingeleitet | BofA/Merrill | Buy |
| 2020-05-26 | Eingeleitet | Jefferies | Buy |
| 2020-05-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Lyra Therapeutics Inc Aktie (LYRA) Neueste Nachrichten
Is Lyra Therapeutics Inc. a good long term investmentBreakthrough capital growth - Autocar Professional
What drives Lyra Therapeutics Inc. stock priceExponential wealth increase - jammulinksnews.com
Lyra Therapeutics (LYRA) Proposes Sale of 846,744 Shares of Comm - GuruFocus
What analysts say about Lyra Therapeutics Inc. stockExceptional trading performance - jammulinksnews.com
Lyra Therapeutics Inc. Stock Analysis and ForecastOver 200% growth - Autocar Professional
How Lyra Therapeutics Inc. stock performs during market volatilityFree Predictions - Newser
Why Lyra Therapeutics Inc. stock attracts strong analyst attentionConsistent High Return Strategy - beatles.ru
What makes Lyra Therapeutics Inc. stock price move sharplyFree Stock Market Courses - Newser
Lyra Therapeutics CFO Cavalier sells $6k in shares By Investing.com - Investing.com Canada
Lyra Therapeutics CEO Palasis sells $13944 in stock By Investing.com - Investing.com Nigeria
Lyra Therapeutics CEO Palasis sells $13944 in stock - Investing.com
Lyra Therapeutics (NASDAQ:LYRA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Lyra Therapeutics Secures $4.3M in Direct Offering - TipRanks
Is Lyra Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
Lyra Therapeutics regains Nasdaq compliance as stock maintains $1 minimum - Investing.com
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Stake Lessened by Two Sigma Investments LP - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why - sharewise
H.C. Wainwright lifts Lyra Therapeutics stock target to $16 By Investing.com - Investing.com Canada
Lyra Therapeutics (LYRA) Price Target Raised by HC Wainwright & Co. | LYRA Stock News - GuruFocus
H.C. Wainwright Ups Target Price for Lyra Therapeutics (LYRA) to $16 | LYRA Stock News - GuruFocus
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Sold by Two Sigma Advisers LP - Defense World
Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - MSN
Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win - insights.citeline.com
Northern Trust Corp Has $59,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Study: LYR-210 Shows Promise in Chronic Rhinosinusitis With Nasal Polyps - Pharmacy Times
BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Finanzdaten der Lyra Therapeutics Inc-Aktie (LYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lyra Therapeutics Inc-Aktie (LYRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):